Malaria elimination: Vaccines should be tested on larger gro
Malaria continues to be a major public health challenge; killing 438,000 people every year and being the leading cause of death in children worldwide. Before a malaria vaccine may be tested on a large group of people, there must be sufficient evidence for a relevant and beneficial effect, with minimal risks and side effects. Few candidate vaccines meet these requirements.

Over the past ten years, only 40 of the many candidate vaccines were actually clinically tested on humans. Only one vaccine (RTS,S vaccine) appears to be promising, which means that children are 45.7 percent protected from malaria for 18 months after vaccination. "By vaccinating a larger group of people in clinical studies with a candidate vaccine in the early testing phase, we increase the likelihood of finding a greater number of promising vaccines, and therefore also accelerate the discovery of an effective vaccine against this disease", says Luc Coffeng, researcher at Erasmus MC's Department of Public Health.